Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2012

01.07.2012 | Article

Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids

verfasst von: S. Tobudic, W. Poeppl, C. Kratzer, A. Vychytil, H. Burgmann

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Peritoneal dialysis used in the treatment of patients with end-stage renal failure is often complicated by peritonitis. Staphylococcus aureus peritonitis is severe, particularly if caused by a methicillin-resistant strain (MRSA). Intraperitoneal administration of drugs for treatment of peritonitis is preferable to intravenous or oral routes because of the resulting higher local antibiotic concentrations. However, peritoneal dialysis fluids (PDFs) have a bacteriostatic effect, which may compromise the efficacy of antibiotics. The bactericidal efficacy of vancomycin, teicoplanin, daptomycin and ceftobiprole was studied in the PDFs Dianeal PD4® (glucose 1.36%), Physioneal 40® (glucose 1.36%), Extraneal® (7.5% icodextrin), and Nutrineal PD4® (1.1% amino acid) using time-kill curves. To simulate in vivo conditions, human serum albumin was added at a final concentration of 2 g/l. All four PDFs had a bacteriostatic effect on the growth of the MRSA test isolate. All antibiotics showed less activity in PDFs compared to control broth. Vancomycin and teicoplanin achieved the greatest reduction in bacterial numbers in the amino-acid containing PDF Nutrineal PD4®. Daptomycin showed its highest activity in Extraneal® and better overall efficacy than the other tested antibiotics. Ceftobiprole showed no killing activities in any of the four PDFs. Based on these in vitro data we conclude that the choice of PDFs for intraperitoneal administration is not trivial and could be crucial for therapy outcome.
Literatur
1.
Zurück zum Zitat Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L (2005) Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25(2):107–131PubMed Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L (2005) Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25(2):107–131PubMed
2.
Zurück zum Zitat Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, Rosales M, Villaverde P, Valdes F (2005) Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 25(3):274–284PubMed Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, Rosales M, Villaverde P, Valdes F (2005) Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 25(3):274–284PubMed
3.
Zurück zum Zitat Fried L, Abidi S, Bernardini J, Johnston JR, Piraino B (1999) Hospitalization in peritoneal dialysis patients. Am J Kidney Dis 33(5):927–933PubMedCrossRef Fried L, Abidi S, Bernardini J, Johnston JR, Piraino B (1999) Hospitalization in peritoneal dialysis patients. Am J Kidney Dis 33(5):927–933PubMedCrossRef
4.
Zurück zum Zitat Fried LF, Bernardini J, Johnston JR, Piraino B (1996) Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7(10):2176–2182PubMed Fried LF, Bernardini J, Johnston JR, Piraino B (1996) Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7(10):2176–2182PubMed
5.
Zurück zum Zitat Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ (2002) Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 39(6):1278–1286PubMedCrossRef Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ (2002) Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 39(6):1278–1286PubMedCrossRef
6.
Zurück zum Zitat Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG (2010) Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30(4):393–423PubMedCrossRef Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG (2010) Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30(4):393–423PubMedCrossRef
7.
Zurück zum Zitat Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A (1986) Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother 29(5):797–802PubMed Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A (1986) Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother 29(5):797–802PubMed
8.
Zurück zum Zitat Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132(5):1297–1304PubMed Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132(5):1297–1304PubMed
9.
Zurück zum Zitat Clouse FL, Hovde LB, Rotschafer JC (2007) In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate. Antimicrob Agents Chemother 51(12):4521–4524PubMedCrossRef Clouse FL, Hovde LB, Rotschafer JC (2007) In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate. Antimicrob Agents Chemother 51(12):4521–4524PubMedCrossRef
10.
Zurück zum Zitat Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47(12):3764–3767PubMedCrossRef Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47(12):3764–3767PubMedCrossRef
11.
Zurück zum Zitat Clinical Laboratory Standards Institute C (2008) Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. Wayne, PA, USA Clinical Laboratory Standards Institute C (2008) Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. Wayne, PA, USA
12.
Zurück zum Zitat Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, Harding G (2000) Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36(5):1009–1013PubMedCrossRef Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, Harding G (2000) Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36(5):1009–1013PubMedCrossRef
13.
Zurück zum Zitat Xu G, Tu W, Xu C (2010) Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 25(2):587–592PubMedCrossRef Xu G, Tu W, Xu C (2010) Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 25(2):587–592PubMedCrossRef
14.
Zurück zum Zitat de Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29(1):5–15PubMed de Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29(1):5–15PubMed
15.
Zurück zum Zitat McDonald WA, Watts J, Bowmer MI (1986) Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 24(1):104–107PubMed McDonald WA, Watts J, Bowmer MI (1986) Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 24(1):104–107PubMed
16.
17.
Zurück zum Zitat Mascio CT, Alder JD, Silverman JA (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51(12):4255–4260PubMedCrossRef Mascio CT, Alder JD, Silverman JA (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51(12):4255–4260PubMedCrossRef
18.
Zurück zum Zitat Carpenter CF, Chambers HF (2004) Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38(7):994–1000PubMedCrossRef Carpenter CF, Chambers HF (2004) Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38(7):994–1000PubMedCrossRef
19.
Zurück zum Zitat Salzer W (2005) Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 25(4):313–319PubMed Salzer W (2005) Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 25(4):313–319PubMed
20.
Zurück zum Zitat Wiggins KJ, Johnson DW, Craig JC, Strippoli GF (2007) Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 50(6):967–988PubMedCrossRef Wiggins KJ, Johnson DW, Craig JC, Strippoli GF (2007) Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 50(6):967–988PubMedCrossRef
Metadaten
Titel
Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids
verfasst von
S. Tobudic
W. Poeppl
C. Kratzer
A. Vychytil
H. Burgmann
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2012
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1446-0

Weitere Artikel der Ausgabe 7/2012

European Journal of Clinical Microbiology & Infectious Diseases 7/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.